Reprinted, with permission, from Progression of retinopathy with intensive versus conventional treatment in the Diabetes Control and Complications Trial Research Group, Ophthalmology Journal. San Francisco, California: American Academy of Ophthalmology; 1995.
File Size:
58 KB
Retina/Vitreous
The Diabetes Control and Complications Trial (DCCT), a prospective clinical trial sponsored by the NIH, recruited 1400 patients with insulin-dependent (type 1) diabetes in the United States and Canada. Patients with no baseline retinopathy and patients with mild to moderate nonproliferative diabetic retinopathy (NPDR) were randomized between two treatment groups—conventional or intensive therapy. The DCCT demonstrated that intensive glucose control reduces the rate of development and progression of diabetic retinopathy in type 1 patients with and without baseline retinopathy.